Cholestin claims revision would not change "implied intent" of marketing -- NCL.
This article was originally published in The Tan Sheet
Executive Summary
PHARMANEX CHOLESTIN CLAIMS REVISION WOULD NOT CHANGE "IMPLIED INTENT" of the product's marketing and "may encourage individuals to take the product without first consulting with a physician about their cholesterol levels," the National Consumers League tells FDA in Jan. 30 comments. Current claims for the product are unapproved drug claims and changing them to "maintains or promotes healthy cholesterol" does not "change the implied intent of the product" as a cholesterol-reducing agent, NCL states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning